15 jun: IMF OKs Terms for Funds Pledged to Boost Resources
16 jun: Monsanto to Invest $355 Million in Argentina Corn-Seed Plant
15-06-2012 23:53:00

Merck Loses Nasonex Patent Suit; Says Likely to Appeal

Relateret indhold

By Ben Fox Rubin

Drug maker Merck & Co. (MRK) said a U.S. district court ruled against it in a patent-infringement suit involving Apotex Inc.

In 2009, Merck filed the suit in New Jersey in an effort to block Apotex, a Canadian generic drug manufacturer, from selling a generic copy of Merck's blockbuster allergy drug Nasonex before U.S. patent protection expires.

Apotex had challenged the validity of the U.S. patent covering Nasonex. Merck said its patent for Nasonex is due to expire in 2018.

Bruce N. Kuhlik, Merck's general counsel, said his company was pleased the court ruled that its patent on Nasonex is valid, but was disappointed the court said the patent wasn't infringed by Apotex's product.

"Today's decision reflects just one step in the lengthy patent litigation process, and we plan to review all of our options, including a likely appeal of the decision," Mr. Kuhlik said.

Merck, like its rivals, has been cutting costs as part of an effort to soften the hit from increased generic competition. The company's top-selling allergy and asthma medication Singulair loses patent exclusivity in August and the ripple-effect from generic versions of rival Pfizer Inc.'s (PFE) cholesterol fighter Lipitor have contributed to a decline in sales of Merck's anticholesterol drug Vytorin.

In April, Merck said its first-quarter earnings rose 67% as the drug maker's cost controls helped offset slower-than-expected sales growth.

Shares closed Friday at $38.94 and were down 14 cents after hours. The stock is up 3.3% year-to-date.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

(END) Dow Jones Newswires

June 15, 2012 17:53 ET (21:53 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Danske: Bestyrelsesmedlem køber aktier for 236.748 kr.

24-07-2014 16:39:27
Carol Sergeant, der er medlem af bestyrelsen hos Danske Bank, har købt aktier i banken for samlet 236.748 kr. torsdag.Det fremgår af en insidermeddelelse torsda..

Novo: Konkurrent vender tilbage til stærk vækst i insulinsalget

24-07-2014 12:46:29
Amerikanske Eli Lilly, der er en stor konkurrent til Novo Nordisk på insulinmarkedet, leverede tocifret vækst i salget af sit bedst sælgende insulin, Humalog, i..

Aktier/åbning: Danske Bank dominerer efter dukseregnskab

24-07-2014 09:29:28
Danske Bank er der store historie torsdag morgen på det danske aktiemarked, efter at banken har leveret sit bedste kvartalsresultat siden 2007. Det bliver beløn..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Danske Q2: Massiv fremgang og opjustering
2
Aktier/tendens: Danske Bank stjæler rampelyset
3
Aktier/åbning: Danske Bank dominerer efter dukseregnskab
4
Novo: Konkurrent vender tilbage til stærk vækst i insulinsalget
5
TDC/analytikere: Telia-køb af Telenor Danmark mest sandsynligt

Relaterede aktiekurser

Merck & Co., Inc 58,21 0,2% Stigning i aktiekurs
Merck AND CO Inc 42,60 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
25. juli 2014 05:43:58
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20140723.1 - EUROWEB5 - 2014-07-25 05:43:58 - 2014-07-25 05:43:58 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x